Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction [Original Articles]

Conclusions— These findings indicate that dual ET-A/ET-B receptor inhibition improves HFpEF by abrogating adverse cardiac remodeling via antihypertrophic mechanisms and by reducing stiffness. Additional studies are needed to explore the role of dual ET-1 receptor antagonists in patients with HFpEF.

http://circheartfailure.ahajournals.org/cgi/content/short/9/11/e003381?rss=1

Source: Circulation: Heart Failure - November 2, 2016 Category: Cardiology Authors: Valero-Munoz, M., Li, S., Wilson, R. M., Boldbaatar, B., Iglarz, M., Sam, F. Tags: Heart Failure, Hypertrophy, Remodeling Original Articles Source Type: research